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contains an ICD-O3-TOPO, which provides a topographical identifier for different organs (e.g. C220: Liver; C339: Trachea), and an ICD-O3-MORPH, which provides basic and detailed description of pathology (e.g. respectively: 801: Carcinoma, NOS (not otherwise specified); 8013/3: Large cell neuroendocrine carcinoma; 922: Chondrosarcoma, NOS; 9221/3: Juxtacortical chondrosarcoma). A "/0" means: benign tumor (e.g.: 9220/0: Chondroma): "/1" means: borderline malignancy (e.g. 9751/1: Langerhans cell histiocytosis); "/2" means: malignant tumor in situ (e.g. 8500/2: Intraductal carcinoma, noninfiltrating, NOS); and "/3" means full malignancy. Nosology, thesaurus and census, with phylum of solid tumors and hematological malignancies can be found in the Atlas at: http://atlasgeneticsoncology.org/Tumors/Solid_Nos ology.html and: http://atlasgeneticsoncology.org/Anomalies/ICDO_Hematology.html. This classification is not used by all databases (e.g. the Mitelman database and the COSMIC database use different classifications, with no apparent matching). This makes any integration of data by new resources complicated.
III-Nucleic acid, genes and protein databases III-1 Nucleic acid databases
The first database for DNA sequencing was The Los Alamos Sequence Database in 1979, which was consequently replaced by public GenBank ((http://www.ncbi.nlm.nih.gov/genbank/) (Burks C et al., 1985) in 1982. The database was funded by the National Institutes of Health, the National Science Foundation, the Department of Energy, and the Department of Defense. Los Alamos National Laboratories (LANL) collaborated with several firms like Bolt, Beranek, and Newman to increase the size of the database. By the end of 1983 more than 2,000 sequences were stored in it.
Mid 1980s, the Intelligenetics bioinformatics company from Stanford University collaborated with LANL to manage the GenBank project (Burks C et al., 1991) . Since it was one of the earliest bioinformatics community projects on the Internet, BIOSCI/Bionet news groups was created to promote open access communications among bioscientists. From 1989 to 1992, the GenBank project transitioned to the newly created National Center for Biotechnology Information (Benton D, 1990) . From 1982 to present day, the number of bases in GenBank has doubled roughly every 1,5 years (Benson DA et al., 2015) . As of February 2016, GenBank version 212.0 contains 190,250,235 loci, 207,018,196,067 bases, from 190,250,235 reported sequences (http://www.ncbi.nlm.nih.gov/genbank/statistics/). The GenBank database includes additional data sets that are constructed mechanically from the main sequence data collection, and therefore are excluded from this count. In parallel, the EMBL database was created in 1981 and since this date there is an International Nucleotide Sequence Database Collaboration (INSDC) which is a long-standing foundational initiative that operates between DDBJ, EMBL-EBI and NCBI. INSDC covers the spectrum of data raw reads, though alignments and assemblies to functional annotation, enriched with contextual information relating to samples and experimental configurations. In particular there are numerous evolutions with the development of massive sequencing with creation of more integrated structures as ENA (European Nucleotide Archive at EBI, http://www.ebi.ac.uk/services/dnarna) or SRA (Sequence read archive at NCBI, http://www.ncbi.nlm.nih.gov/sra/) (Cook CE et al., 2016) . In parallel with the genome projects, the need for the best representation of genomic and transcript sequences for diverse species has been the driver for creating consensus databases (as RefSeq, UCSC, Ensembl) with several methods of optimisation.
III-2 Genes and Functions

Genomic sequences and transcripts
As mentioned in the general resources, several consensus nucleic sequence databases provide detailed structures of genes and isoforms. All the information can easily be visualized using different browsers (UCSC, Ensembl) or described in detail on the Entrez Gene (see above) page at NCBI. RefSeq (http://www.ncbi.nlm.nih.gov/refseq/) maintains and curates a database recording annotated genomic, transcript, and protein sequences. RefSeq release 71 provides sequences from over 55,000 organisms (more than 4,800 viruses, 40,000 prokaryotes and 10,000 eukaryotes) (O'Leary NA et al., 2016) . Ensembl (http://www.ensembl.org/) is a joint project between EMBL-EBI and the Wellcome Trust Sanger Institute to develop a software which develops and maintains automatic annotation of selected eukaryotic genomes (Gray KA et al., 2015) . The UCSC Genome Browser database is a large collection of 160 genome assemblies representing 91 species (Rosenbloom KR et al., 2015) (Figures 2 and 3: PAX5 at UCSC and at the Atlas site respectively). Some standardisation within CCDS and GenCode http://www.gencodegenes.org/ gives an up-to-date information on them. The nature of isoforms, expressed differently in normal tissues and in tumors, due to splicing variety, leads to protein product with different amino acid sequences. This reflects the variations in the structure in domains and in the 3D structure are the basis of the activity. On the other hand, the level of expression of transcript in different tissues can be obtained from SOURCE, GEO (Clough and Barett, 2016 ) , Expression Atlas ( Petryszak et al., 2016) , Gene expression viewer (Firebrowse), BioGPS (http://biogps.org/#goto=welcome) (Figure 4 ).
III-3 Protein sequence databases
In parallel with the nucleic databases, the first protein database was established by M. Dayhoff as NBRF protein database in 1983, in continuity of the first comprehensive collection of macromolecular sequences in the Atlas of Protein Sequence and Structure, published from 1965-1978. This was followed by the development of SwissProt, a curated dataset, by Amos Bairoch in 1986 (http://www.isb-sib.ch/sp30/the-history-ofswiss-prot). With collaboration between the Swiss Institute of Bioinformatics and the EBI to lead in 2002 (in association with the PIR database) the SwissProt was extended to UniProt Knowledgebase (UniProtKB) in 1998, consisting in the curated UniProtKB/Swiss-Prot databank, its automatically annotated supplement TrEMBL, and the PIR protein database. Today, UniProtKB represents the world's most comprehensive catalogue of information on proteins. In the space of 30 years, the number of proteins entered in UniProtKB/Swiss-Prot has increased from 4,000 to 550,000 : 550,960 entries for the SwissProt part and 63,686,057 entries for the non-reviewed part for TrEMBL (Pundir S et al., 2015) .
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De Braekeleer E, et al. Atlas Genet Cytogenet Oncol Haematol. 293 (Gaudet P et al., 2015) is a resource for human proteins, including information on the exons, proteins sequences, function, subcellular localisation, expression, interactions and role in diseases ( Figure 6 ). The major part of the information in neXtProt is obtained from the UniProt Swiss-Prot database but is gradually being complemented by original data. neXtProt contains 20,055 protein entries, and is maintained by Amos Bairoch at the Swiss Institute of Bioinformatics and GeneBio.
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PhosphoSitePlus
(http://www.phosphosite.org/homeAction.action) PhosphoSitePlus (Hornbeck PV et al., 2015) is an excellent resource providing comprehensive information and tools for the study of protein posttranslational modifications (PTMs) including phosphorylation, ubiquitination, acetylation and methylation ( Figure 7 (Mitchell A et al., 2015) .
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Figure 8: and 9: JAK2 and SQSTM1 at Atlas: protein domains (http://atlasgeneticsoncology.org//Genes/JAKID98.html and http://atlasgeneticsoncology.org//Genes/GC_SQSTM1.html) There are also data and iconography on pathways ( Figure 10 ).
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Atlas of Genetics and Cytogenetics in Oncology and Haematology
The Atlas presents highly curated paragraphs with the description of the protein listing domains and iconography, expression and localisation, function, homologs, and uniquely, a wide angle on cancers and other medical conditions where a gene or a protein is implicated (Figure 8 and 9). ;..) with output in different formats. Once a result is obtained as a list of gene symbols, it is possible to link it to related data in another part of the Entrez database (e.g. list of publication in PubMed from a selected list of genes symbols) (NCBI Resource Coordinators, 2016).
IV-Cards
IV-2 Genecards (http://www.genecards.org/)
Genecards is an integrative database that provides comprehensive, user-friendly information on all annotated and predicted human genes. It automatically integrates data from roughly 125 web sources and includes genomic, transcriptomic, proteomic, genetic, clinical and functional information.
There are some affiliated databases as MalaCards "The human disease database" (http://www.malacards.org/) which is an integrated database of human diseases and their annotations, modeled on the architecture and richness of the GeneCards database of human genes (Fishilevich S et al., 2016) .
V-Genome cartography
The cartography of genes on a genome has been the favoured mean to represent genomic information. With the human Genome Project, several types of viewers have been developed. To date, two sites are of first interest for human genetics:
V-1 UCSC (http://genome.ucsc.edu/) and UCSC-Cancer (https://genomecancer.ucsc.edu/.)
The UCSC Genome Browser contains a reference sequence and working draft assemblies for a large collection of genomes. It also provides portals to ENCODE data at UCSC (2003 to 2012). The Genome Browser zooms and scrolls over chromosomes, presenting the work of annotators worldwide. The "Gene Sorter" shows expression, homology and other information on groups of genes that can be related in many ways (with a chosen set of tracks). "Blat" maps sequences to the genome quickly. The Table Browser provides convenient access to the underlying database. "VisiGene" lets you browse through a large collection of in situ mouse and frog images to examine gene expression patterns. "Genome Graphs" allows you to upload and display genome-wide data sets. The UCSC Genome Browser is developed and maintained by the Genome Bioinformatics Group, a crossdepartmental team within the UC Santa Cruz Genomics Institute at the University of California Santa Cruz (UCSC). A parallel browser has been developed for visualizing and analysing cancer data. The UCSC Cancer Browser https://genomecancer.ucsc.edu/proj/site/help/) allows researchers to explore cancer genomics data and its associated clinical information in an interactive manner. Data can be viewed in several different ways, including by value, chromosome location, clinical features, biological pathways or genes of interest. It is also possible to quickly perform and easily view statistical analysis on subsets of the data. The data heatmap displays genome-wide data from copy number, transcriptome, protein, epigenetic, mutation, sh/siRNA, and PARADIGM pathway analysis studies as well as associated clinical information. The left column shows datasets that are currently in view along with a button to add more. Today the system has 720 datasets for an exploration (Goldman M et al., 2015) .
V-2 Ensembl (http://www.ensembl.org)
Ensembl produces genomic datasets through a system that is designed to analyse, store and distribute data, and which enables interpretation through open data release. As a hub of reference and baseline data similar to UCSC Genome Browser and RefSeq, Ensembl also distributes created datasets and promotes standards and interoperability between genomic resources. In addition, Ensembl collaborates with and often plays active leadership roles in projects such as ENCODE, the "Genome Reference Consortium" (GRC), the "Global Alliance for Genomics and Health" (GA4GH) and GENCODE. Ensembl is updated 4-5 times annually with each release representing a data and software freeze. Ensembl provides two sets of human data based on the hg19 genome build (http://grch37.ensembl.org/Homosapiens/Info/Index ) which has been updated by the data set based on the December 2013 Homo sapiens high coverage assembly GRCh38 from the Genome Reference Consortium. This assembly is used by UCSC to create their hg38 database. The data set consists of gene models built from the alignments (for comparison) of the human proteome as well as from alignments of human cDNAs. This release of the assembly has the following properties: assembly length with a total of 3.4 Gb, chromosome length total 3.1 Gb (excluding haplotypes). It also includes 261 alternate loci scaffolds, mainly in the LRC/KIR complex on chromosome 19 (35 alternate sequence representations) and the MHC region on chromosome 6 (7 alternate sequence representations) (Yates A et al., 2016) .
VI-Structural variation databases
Since the mid 2000's, there were several studies of copy number variation of DNA sequences to construct CNV map of the human genome through different populations using SNP genotypes and CGH (Iafrate AJ et al., 2004; Redon R et al., 2006) . It is becoming clear that genomic structural variation (variation ranging from tens to millions of base pairs in size, and including insertions, deletions, inversions, translocations and locus copy number changes) accounts for individual differences at the DNA sequence level in humans and can play a major role in diseases. Many databases have integrated data produced in the literature. DECIPHER (DatabasE of Genomic variants and Phenotype in Humans using Ensembl Resources) is an interactive web-based database which incorporates a series of tools designed to aid the interpretation of genomic variants. DECIPHER enhances clinical diagnosis by retrieving information from a variety of bioinformatics resources relevant to the variant found in a patient. The patient's variant is displayed in the context of both normal variation and pathogenic variation reported at that locus, thereby facilitating interpretation (Firth HV et al., 2009 ).
VI-1 dbVar
VI-4 1000 Genomes (http://www.1000genomes.org/)
The 1000 Genomes Project beneficiated from the progress in sequencing technology, which sharply reduced the cost of sequencing. It was the first project to sequence the genomes of a large number of people, to provide a comprehensive resource on human genetic variation. Data from the 1000 Genomes Project was quickly made available to the worldwide scientific community through freely accessible public databases. In continuation of the 1000 Genome project (sequencing 1000 human genome as exomes or whole genomes), the International Genome Sample Resource (IGSR) aims to expand information to new populations, a better coverage for presenting a uniform analysis set. Data corresponds to both single nucleotide and structural variants (1000 Genomes Project Consortium et al., 2015 . The 1000 Genomes Project operated between 2008 and 2015, creating the largest public catalogue of human variation and genotype data. As the project ended, the Data Coordination Centre at EMBL-EBI received continuous funding from the Wellcome Trust to maintain and expand the resource. The International Genome Sample Resource (IGSR) is maintaining and extending the 1000 Genomes Project data.
VII-Polymorphism databases
It is important to distinguish between polymorphisms due to a change in a single nucleotide (SNP) as the variability within a population and mutations acquired in a neoplastic process. The determination of variants was previously obtained by SNP arrays, but is nowadays performed by massive parallel sequencing. As a result, a huge quantity of polymorphisms and mutations in tumors are compared to controls. The landscape of the majority of recurrent mutations is now known and can be used for diagnosis. 
VII-1 dbSNP
VII-3 1000 Genomes Project (see above)
As the Phase3, 1000 Genomes variants are in the process of being archived at dbSNP and DGVa and a version of the Ensembl databases has been created, containing the phase3 autosomal variants. This is presented alongside the v80 GRCh37 Ensembl core and regulatory databases. This release represents more than 80M short variants with genotypes for 2,504 individuals across 26 populations. The latest major update was realeased to the 1000 Genomes Website in February 2016 (1000 Genomes Project .
VII-4 Exome Variant server (EVS) (http://evs.gs.washington.edu/EV S/)
The goal of the NHLBI GO Exome Sequencing Project (ESP) is to discover novel genes and mechanisms contributing to heart, lung, and blood
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De Braekeleer E, et al. Atlas Genet Cytogenet Oncol Haematol. disorders by pioneering the application of nextgeneration sequencing of the protein coding regions of the human genome across diverse, richlyphenotyped populations and to share these datasets and findings with the scientific community to extend and enrich the diagnosis, management and treatment of the aforementioned disorders. Two categories of populations are considered: EuropeanAmerican and African-American. Some criteria or impact scores of the variation on the gene function are also presented (Tennessen JA et al., 2012) . (Figure 11 ). TCGA surpassed that goal, characterizing 33 different cancer types including 10 rare cancers (http://cancergenome.nih.gov/abouttcga/overview). Funding is split between genome characterization centers (GCCs), which perform the sequencing, and genome data analysis centers (GDACs), which perform the bioinformatic analyses. The project scheduled 500 patient samples using several analysing techniques: Gene expression profiling, copy number variation profiling, SNP genotyping, genome wide DNA methylation profiling, microRNA profiling, and exon sequencing of 1,200 or more genes ( Figure 12 ). TCGA is sequencing some tumors, including at least 6,000 candidate genes and microRNA sequences. This targeted sequencing is being performed by all three sequencing centers using hybrid-capture technology. In phase II, TCGA is performing whole exon sequencing on 80% of the cases and whole genome sequencing on 80% of the cases used in the project. 
VIII-Portals
VIII-2 ICGC (https://icgc.org/)
ICGC (The International Cancer Genome Consortium) was organized to launch and coordinate a large number of research projects with the common aim of comprehensively elucidating the genomic changes present in many forms of cancers. Funding and Research members proposing a project must agree to the ICGC's policies ( Figure 13 ). ICGC's primary objectives are to generate comprehensive catalogues of genomic abnormalities (somatic mutations, abnormal expression of genes, epigenetic modifications) in tumors representing 50 different cancer types and/or subtypes which are of clinical and societal importance across the globe and make the data available to the entire research community. Each of the 50 projects will generate the genomic analyses on approximately 500 cancer samples of each class. This will cover the various types and subtypes but cannot exhaustively cover the full spectrum of cancer types. The ICGC facilitates communication among the members and provides a forum for coordination with the objective of maximizing efficiency among the scientists working to understand, treat, and prevent these diseases. ICGC data release 20 (November 2015) comprises data from 14,767 cancer genomes in total. The ICGC Data Portal (https://dcc.icgc.org/) is developed by the Ontario Institute for Cancer research (OICR) (Zhang J et al., 2011) . VIII-3 OASIS (http://www.oasis-genomics.org/) OASIS, which was created by Pfizer Oncology Research Computational Biology in collaboration with Research Business Technology (RBT), is an open-access web portal that provides the possibility to run exploratory and integrative analyses of somatic mutations, copy number variation (CNV) and gene expression data (Figure14). This data originates from thousands of different tissues of tumour samples, normal tissues and cell lines thus representing a broad spectrum of malignancies. This portal contains 30 datasets, mainly from TCGA, with access to mutations, copy number variation, expression (microarrays) and expression (RNA-Seq).
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VIII-4 Firebrowse (http://firebrowse.org/)
This portal developed at the Broad Institute presents 38 cancer cohorts and 14,729 samples, mainly from the TCGA program, and provides an option to browse reports, clinical analysis, copy number variation, mutation, expression, and to download data for further analysis (Figure 15 ) See the tutorial for a complete view of possibilities (http://firebrowse.org/tutorial/FireBrowseTutorial.pdf).
VIII-5 GDC (https://gdc.nci.nih.gov/)
The NCI's Genomic Data Commons (GDC) provides the cancer research community with a unified data repository that enables data sharing across cancer genomic studies in support of precision medicine. (note added in proof, June 6, 2016). The GDC supports several cancer genome programs at the NCI Center for Cancer Genomics (CCG), including The Cancer Genome Atlas (TCGA), Therapeutically Applicable Research to Generate Effective Treatments (TARGET), and the Cancer Genome Characterization Initiative (CGCI). The GDC Data Portal provides a platform for efficiently querying and downloading high quality and complete data. The GDC also provides a GDC Data Transfer Tool and a GDC API for programmatic access.
IX-Impact on diseases
IX-1 OMIM
"Mendelian Inheritance in Man: Catalogs of Autosomal Dominant, Autosomal Recessive and Xlinked Phenotypes" was first published in 1966 by Victor A. McKusick (Johns Hopkins University Press), after a catalog of X-linked traits, published in 1962. In parallel, the "Human Gene Mapping" was first organized in New Haven in 1973, and mapped 119 and 100 loci respectively to confirmed or provisional/tentative chromosome assignements (Birth Defect, 1974) . The first edition of the "Mendelian Inheritance in Man: Catalogs of Autosomal Dominant, Autosomal Recessive and X-linked Phenotypes" had 1487 entries and no mapped autosomal loci. Victor A.
McKusick published 12 editions, the last one in 1998, of his catalog. "Online Mendelian Inheritance in Man" (OMIM, http://omim.org/) was consequently published online. OMIM is a continuously updated catalog of human genes and genetic disorders and traits, with particular focus on the molecular relationship between genetic variation and phenotypic expression (Amberger JS et al., 2015) .
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De Braekeleer E, et al. Atlas Genet Cytogenet Oncol Haematol. As of April 2016, it consists of 23,460 entries: 15,237 gene descriptions, 4,705 phenotypes with known molecular basis, an additional 1,626 phenotypes with unknown molecular basis, and 1892 other entries. Gene entries start at: * 100640. Aldehyde dehydrogenase 1 family, member A1; ALDH1A1 Cytogenetic location: 9q21.13, Genomic coordinates (GRCh38): 9:72,900,661-72,953,316, and ends with * 616906. Cancer susceptibility candidate 1; CASC1. Phenotypes with known molecular basis entries start at: # 100100. Prune belly syndrome; PBS, Cytogenetic location: 1q43, and ends with # 616903. Nucleoside diphosphate-linked moiety X motif 15 deficiency; NUDT15D. OMIM describes somatic mutations in genes (11,139 entries for the term "mutation"). It is a very well curated database, with excellent reliability. Unfortunately the addition process of data as literature is published, by successive layerings/sedimentation makes it sometimes a laborious consultation. OMIM is authored and edited at the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine.
IX-2 ClinVar (http://www.ncbi.nlm.nih.gov/clin var/intro/)
ClinVar is designed to provide a public archive of reports of the relationships among human variations and phenotypes, with supporting evidence. By doing so, ClinVar facilitates access to and communication about the relationships asserted between human variation and observed health status, and the history of that interpretation. ClinVar collects reports of variants found in patient samples, and assertions made regarding their clinical significance. The alleles described in submissions are mapped to reference sequences, and reported according to the HGVS standard. ClinVar then presents the data for interactive users in daily workflow and other local applications. ClinVar works in collaboration with interested organizations to meet the needs of the medical genetics community as efficiently and effectively as possible (Harrison SM et al., 2016) .
IX-3 MedGen (http://www.ncbi.nlm.nih.gov/med gen/)
MedGen is an NCBI portal of information about human disorders and other phenotypes having a genetic component. MedGen is structured to serve health care professionals, medical genetics community and other interested parties by providing centralized access to diverse content. MedGen aggregates the plethora of terms used for particular disorders into a specific concept, providing a "Rosetta stone" for stakeholders who may use different names for the same disorder.
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De Braekeleer E, et al. Atlas Genet Cytogenet Oncol Haematol. Maintaining a clearly defined set of concepts and terms for phenotypes is essential in supporting characterization of genetic variation by its specific phenotypes effect. The assignment of identifiers for those concepts allows computational access to phenotypic information, an essential requirement for the large-scale analysis of genomic data. (NCBI Resource Coordinators, 2016) .
IX-4 dbGaP (http://www.ncbi.nlm.nih.gov/dbg ap/)
The database of Genotypes and Phenotypes (dbGaP) was developed to archive and distribute the data and results from studies where the interaction of genotype and phenotype in Humans has been investigated.
IX-5 SNPs3D (http://www.snps3d.org/)
SNPs3D is a website which assigns molecular functional effects of non-synonymous SNPs based on structure and sequence analysis. The site presents a data mining method to infer candidate SNP for 16 types of cancer (e.g. more than 1,000 genes potentially implicated in breast cancer: http://www.snps3d.org/modules.php?name=Candid ate&disease=BREAST%20CANCER) (Yue P and Moult J, 2006 ).
IX-6 GTR (http://www.ncbi.nlm.nih.gov/gtr/)
The Genetic Testing Registry (GTR) provides a central location for voluntary submission of genetic test information by providers. The scope includes purpose of the test, methodology, validity, evidence of its usefulness and laboratory contacts and credentials. The overarching goal of the GTR is to advance public health research to include the genetic basis of health and disease (Rubinstein WS et al., 2013) .
IX-7 ClinGen (https://www.clinicalgenome.org/)
ClinGen is a National Institutes of Health (NIH)-funded resource dedicated to building an authoritative central resource that defines the clinical relevance of genes and variants for use in precision medicine and research. This resource has several goals for building a genomic knowledge base to improve patients care. The WHO/OMS code, the ICD-O3, is not used by all databases (e.g. the Mitelman database or the COSMIC database have their own classification system, with no apparent matching). This is an obstacle for the integration of data by new resources.
X-
X-2 Atlas of Genetics and Cytogenetics in Oncology and Haematology
The Atlas provides complete description of diseases, with papers similar to those found in the "Rosai and Ackerman's Surgical Pathology" or the "WHO/IARC Classification of Tumours series" (see above) with following restrictions: on the one hand, many tumor types are still missing from the Atlas; on the other hand, articles on genes closely related to these diseases are found, right next, in the Atlas, but not in the Rosai nor in the WHO's books, since this is out of their purpose.
X-3 PathologyOutlines (http://pathologyoutlines.com/)
PathologyOutlines provides information to practicing pathologists, with gross and microscopic images and summaries on CD markers and immunohistochemical stains and molecular markers. 
X-4 The
XI-Cancer Registries
Cancer registries are organizations seeking to collect, store, analyze, and report data on various cancers for epidemiological purposes, for providing statistics on the occurrence of cancer in a defined population, and for obtaining a framework to assess the impact of cancer in a given population. Cancer registries are crucial for healthcare policy planning. 
XII-2 interfaces between science and patients
GeneTests (https://www.genetests.org) GeneTests (Pagon RA, 2006) provides information for 4,552 disorders (https://www.genetests.org/disorders/), 5,385 genes (https://www.genetests.org/genes/) (e.g. RUNX1 RUNX1 and contacts with/for: 79,009 laboratory tests (https://www.genetests.org/tests/), 680 laboratories (https://www.genetests.org/laboratories/) and 1,067 clinics (https://www.genetests.org/clinics/). NORD (http://rarediseases.org) NORD provides information on more than 1,300 rare diseases (e.g. Carcinoid syndrome http://rarediseases.org/rare-diseases/carcinoidsyndrome/), state health insurance information, guides for physicians, and patient assistance programs. They also provide grants to academic scientists for translational or clinical studies to help patients obtain life-saving or life-sustaining medication they could not otherwise afford. Orphanet (http://www.orpha.net/) Orphanet (Rath et al., 2012) offers an inventory of rare diseases with data on 5,833 diseases (e.g. Fanconi anaemia), an inventory of orphan drugs, list of 6,636 expert centres and 3,280 laboratories, 19,894 professionals for genetic counselling and medical management. Orphanet does not provide gene annotations. They hold a large partnership from 38 countries participating in the Orphanet consortium. They maintain large disease registries in Europe. 
